Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
ScRNA-seq unveils the functional characteristics of glioma-associated macrophages and the regulatory effects of chlorogenic acid on the immune microenvironment-a study based on mouse models and clinical practice.
Front Immunol
January 2025
Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Introduction: Glioma is the most common primary malignant brain tumor. Despite advances in surgical techniques and treatment regimens, the therapeutic effects of glioma remain unsatisfactory. Immunotherapy has brought new hope to glioma patients, but its therapeutic outcomes are limited by the immunosuppressive nature of the tumor microenvironment (TME).
View Article and Find Full Text PDFFrom Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.
Breast Cancer (Dove Med Press)
January 2025
Immunology Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21859, Saudi Arabia.
Nanoparticle technology has revolutionized breast cancer treatment by offering innovative solutions addressing the gaps in traditional treatment methods. This paper aimed to comprehensively explore the historical journey and advancements of nanoparticles in breast cancer treatment, highlighting their transformative impact on modern medicine. The discussion traces the evolution of nanoparticle-based therapies from their early conceptualization to their current applications and future potential.
View Article and Find Full Text PDFAn integrated strategy for sequential nitrite removal and methane recovery: Sludge fermentation driven by nitrite reduction.
Water Res X
May 2025
National Engineering Laboratory for Advanced Municipal Wastewater Treatment and Reuse Technology, Engineering Research Center of Beijing, Beijing University of Technology, Beijing 100124, PR China.
Although the treatment of sludge with free nitrous acid can effectively recover short chain fatty acids, the feasibility of sequential nitrite reduction and methane recovery without acidic pH adjustment is still scarcely studied. Therefore, this study aimed to provide insights into the effect of nitrite at different levels on nitrite reduction and methane production. The results showed that the nitrite concentrations of 100, 200, 400 and 800 mg/L were completely reduced in 1, 2, 2 and 4 days, respectively.
View Article and Find Full Text PDFAn Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell Cancers.
Health Sci Rep
January 2025
Medical Oncology Healthcare Global Bangalore India.
Background And Aims: Sensitivity to immune checkpoint inhibitor (ICI) therapy depends in part on the genetic and epigenetic makeup of cancer cells, and CD8 T-lymphocytes that mediate immune responses. Epigenetics are heritable reversible changes in gene expression that occur without any changes in the nuclear DNA sequence or DNA copy number.
Primary Objective: i.
Novel multipotent conjugate bearing tacrine and donepezil motifs with dual cholinergic inhibition and neuroprotective properties targeting Alzheimer's disease.
RSC Med Chem
January 2025
Área de Neurofisiología celular, Instituto de Biología, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia Medellín Colombia
In this work, we developed potential multifunctional agents to combat Alzheimer's disease. According to our strategy, fragments of tacrine and donepezil were merged in a unique hybrid structure. After successfully synthesizing the compounds, they were evaluated for their dual AChE/BuChE inhibitor potential and neuroprotector response using a glutamate-induced excitotoxicity model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!